Literature DB >> 18949613

Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.

Mehdi Hamadani1, Farrukh T Awan, Patrick Elder, Thomas S Lin, Pierluigi Porcu, Don M Benson, Kristie A Blum, Steven M Devine.   

Abstract

The transformation of follicular lymphoma (FL) to high-grade histology occurs in up to 70% of FL patients. Studies reporting outcomes of transformed FL patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are scant. Eight FL patients with histologically confirmed transformation to diffuse large B-cell lymphoma underwent HSCT at our institution. The median age was 56 years (range 44-63 years). Median follow-up is 60 months. Progression free survival and overall survival at 4-years for patients undergoing allogeneic HSCT is 56% and 66%, respectively. Four patients developed grade II-IV acute GVHD, whereas four patients had extensive chronic GVHD. Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates.

Entities:  

Mesh:

Year:  2008        PMID: 18949613     DOI: 10.1080/10428190802270902

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.

Authors:  Nishitha Reddy; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

2.  Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma.

Authors:  Frank Heinzelmann; Wolfgang Bethge; Dietrich Wilhelm Beelen; Matthias Stelljes; Peter Dreger; Marianne Engelhard; Jürgen Finke; Nikolaus Kröger; Ernst Holler; Martin Bornhäuser; Annerose Müller; Imme Haubitz; Hellmut Ottinger
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-05       Impact factor: 4.553

3.  Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.

Authors:  Mehdi Hamadani; Don M Benson; Craig C Hofmeister; Patrick Elder; William Blum; Pierluigi Porcu; Ramiro Garzon; Kristie A Blum; Thomas S Lin; Guido Marcucci; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2009-03-09       Impact factor: 5.742

4.  Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

Authors:  Baldeep Wirk; Timothy S Fenske; Mehdi Hamadani; Mei-Jie Zhang; Zhen-Huan Hu; Görgün Akpek; Mahmoud D Aljurf; Philippe Armand; Ernesto Ayala; Veronika Bachanova; Brian Bolwell; Mitchell S Cairo; Amanda Cashen; Yi-Bin Chen; Luciano J Costa; Shatha Farhan; César O Freytes; James L Gajewski; John Gibson; Gregory A Hale; Leona A Holmberg; Jack W Hsu; David J Inwards; Rummurti T Kamble; Dipnarine Maharaj; Richard T Maziarz; Reinhold Munker; Rajneesh Nath; Nishitha M Reddy; Craig B Reeder; David A Rizzieri; Craig S Sauter; Bipin N Savani; Harry C Schouten; Anna Sureda; Julie M Vose; Edmund K Waller; Peter H Wiernik; Robert Peter Gale; Linda J Burns; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-15       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.